AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 290: E26-E33, 2006. First published August 16, 2005; doi:10.1152/ajpendo.00149.2005
0193-1849/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/1/E26    most recent
00149.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamazaki, H.
Right arrow Articles by Zawalich, W. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamazaki, H.
Right arrow Articles by Zawalich, W. S.

Acute and chronic effects of glucose and carbachol on insulin secretion and phospholipase C activation: studies with diazoxide and atropine

Hanae Yamazaki,1 William Philbrick,2 Kathleen C. Zawalich,1 and Walter S. Zawalich1

1Yale University School of Nursing; and 2Department of Internal Medicine, Yale University School of Medicine, Section of Endocrinology and Metabolism, New Haven, Connecticut

Submitted 6 April 2005 ; accepted in final form 10 August 2005


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The acute and chronic effects of 20 mM glucose and 10 µM carbachol on {beta}-cell responses were investigated. Acute exposure of rat islets to 20 mM glucose increased glucose usage rates and resulted in a large insulin-secretory response during a dynamic perifusion. The secretory, but not the metabolic, effect of 20 mM glucose was abolished by simultaneous exposure to 100 µM diazoxide. Glucose (20 mM) significantly increased inositol phosphate (IP) accumulation, an index of phospholipase C (PLC) activation, from [3H]inositol-prelabeled islets. Diazoxide, but not atropine, abolished this effect as well. Unlike 20 mM glucose, 10 µM carbachol (in the presence of 5 mM glucose) increased IP accumulation but had no effect on insulin secretion or glucose (5 mM) metabolism. The IP effect was abolished by 50 µM atropine but not by diazoxide. Chronic 3-h exposure of islets to 20 mM glucose or 10 µM carbachol profoundly reduced both the insulin-secretory and PLC responses to a subsequent 20 mM glucose stimulus. The adverse effects of chronic glucose exposure were abolished by diazoxide but not by atropine. In contrast, the adverse effects of carbachol were abolished by atropine but not by diazoxide. Prior 3 h of exposure to 20 mM glucose or carbachol had no inhibitory effect on glucose metabolism. Significant secretory responses could be evoked from 20 mM glucose- or carbachol-pretreated islets by the inclusion of forskolin. These findings support the concept that an early event in the evolution of {beta}-cell desensitization is the impaired activation of islet PLC.

islets; desensitization; hyperglycemia

HYPERGLYCEMIA EXERTS a time-dependent, adverse effect on the secretory responsiveness of the pancreatic {beta}-cell (9, 10, 22, 52), and a number of maneuvers have been used to interfere with this adverse action (11). Most recently, it has been suggested that diazoxide, a compound that abolishes insulin secretion by preventing closure of the ATP-sensitive potassium (KATP) channel, might prove to be useful in the therapy of diabetes by imposing a period of rest or inactivity on these cells (2, 35). In support of this concept, insulin secretion is enhanced from islets where diazoxide treatment is superimposed upon hyperglycemia (35).

In addition to high glucose (21, 42), chronic sustained exposure to a large number of diverse compounds inflicts a similar secretory lesion on the {beta}-cell (10, 11). These compounds include the cholinergic agonist carbachol (53), the sulfonylurea tolbutamide (41), the fuel secretagogue glucosamine (46), and the adenylate cyclase activator forskolin (44). What these compounds share in common is the ability, after chronic exposure to them, to impair glucose-induced activation of islet phospholipase C (PLC) (43, 49, 52). The activation of this enzyme generates a number of second messengers, including diacyglycerol and inositol phosphates (IP), thought to be intimately involved in the regulation of secretion (28).

Our interest in the role played by PLC in the acute regulation of secretion from control or desensitized islets prompted these studies. Because diazoxide has been advocated in the therapy of diabetes, used to provide a window of rest and recovery, emphasis was also placed on its impact on this signal transduction pathway. Our findings emphasize the significance of PLC in the time-dependent effects that both glucose and cholinergic stimulation exert on the {beta}-cell.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The detailed methodologies employed to assess insulin output from collagenase-isolated islets have been previously described (48, 50). Male Sprague-Dawley rats (weighing 300–375 g) were purchased from Charles River and used in all studies. All animals were treated in a manner that complied with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals, and the Yale University Animal Care and Use Committee approved all studies. The animals were fed ad libitum. After Nembutal (pentobarbital sodium, 50 mg/kg; Abbott, North Chicago, IL)-induced anesthesia, islets were isolated by collagenase digestion and handpicked, using a glass loop pipette, under a stereomicroscope into Krebs-Ringer bicarbonate (KRB) supplemented with 3 mM glucose. They were free of exocrine contamination.

Perifusion studies. Islets were loaded onto nylon filters (Sefar America, Kansas City, MO). Some groups were immediately perifused after the isolation. The islets were perifused in a KRB buffer at a flow rate of 1 ml/min for 30 min in the presence of 5 mM glucose to establish basal and stable insulin secretory rates. After this 30-min stabilization period they were then perifused with the appropriate agonist or agonist combinations, as indicated in the figure legends and in RESULTS. Perifusate solutions were gassed with 95% O2–5% CO2 and maintained at 37°C. Insulin released into the medium was measured by radioimmunoassay (RIA) (1).

Other groups of islets, after being loaded onto nylon filters, were incubated for 3 h. The filter, with islets attached, was placed in a small glass vial. KRB solution (240 µl), supplemented with the compounds listed in RESULTS, was then added. The vials were gently aerated for 10 s with 95% O2–5% CO2 and maintained at 37°C. After 90 min they were aerated again for 10 s. After 3 h they were then perifused as described above.

Islet labeling for IP studies. Groups of 18–26 islets were loaded onto nylon filters and incubated for 1.5–3 h in a myo-2-[3H]inositol-containing KRB solution that was made up as follows: 10 µCi of myo-2-[3H]inositol (specific activity 16–23 Ci/mmol) were placed in a 10 x 75-mm culture tube. To this aliquot of tracer, 255 µl of warmed (to 37°C) and oxygenated KRB medium supplemented with 5 mM glucose ± 10 µM carbachol or 20 mM glucose were added. In additional studies, this incubation medium was supplemented with 100 µM diazoxide or 50 µM atropine as indicated. After mixing, 240 µl of this solution were gently added to the vial with islets. The vial was capped with a rubber stopper, gassed for 10 s with 95% O2–5% CO2, and placed in a metabolic shaker at 37°C. After 90 min, the vials were again gently oxygenated. After the labeling period, the islets were washed with 5 ml of fresh KRB and used for IP measurements.

IP studies. After a washing with 5 ml of fresh KRB to remove free labeled inositol, the islets on nylon filters were placed in small glass vials. Added gently to the vial were 400 µl of warmed (to 37°C) KRB supplemented with 10 mM LiCl to prevent IP degradation and the appropriate agonists as indicated. The vials were capped, and after 30 min the generation of IPs was stopped by adding 400 µl of 20% perchloric acid. Total IPs formed were then measured using Dowex columns, as described previously (6, 38).

Efflux studies. Islets were labeled as described above for the IP studies. However, after the 3-h incubation, these islets were subsequently perifused. Samples (200 µl) were analyzed every 2 min for [3H]inositol radioactivity from minutes 28 to 70 of the perifusion. Fractional efflux rates were calculated as described previously (12, 37, 39).

Glucose utilization rates. The usage of glucose was measured by determining the rate of 3H2O formation from [5-3H]glucose. After isolation, groups of 15–20 islets were incubated in 125 µl of 5–20 mM glucose supplemented with tracer [5-3H]glucose. In some experiments, diazoxide or carbachol was also included where indicated. The 3H2O formed during the subsequent 1-h incubation was separated from the unused [3H]glucose as described previously (36). In additional studies, islets were first incubated for 3 h with 5 mM glucose alone, 20 mM glucose alone, or 10 µM atropine plus 5 mM glucose before usage of 20 mM glucose was measured.

Total islet insulin. After the perifusion, the islets still on filters were retrieved and placed in small glass vials. Hanks' balanced salt solution (250 µl) was gently added, and the samples were sonicated for 20 s. Aliquots were then frozen for the subsequent analysis of insulin content.

Reagents. Hanks' balanced salt solution was used for the islet isolation. The perifusion medium consisted of 115 mM NaCl, 5 mM KCl, 2.2 mM CaCl2, 1 mM MgCl2, 24 mM NaHCO3, and 0.17 g/dl bovine serum albumin. The 125I-labeled insulin for the insulin assay, [3H]inositol, [5-3H]glucose, and 3H2O for the glucose usage studies were purchased from PerkinElmer Life Sciences (Boston, MA). Bovine serum albumin (RIA grade), glucose, carbachol, atropine, diazoxide, and the salts used to make the Hanks' balanced salt solution and perifusion medium were purchased from Sigma (St. Louis, MO). Forskolin was purchased from Calbiochem (La Jolla, CA). Rat insulin standard (lot no. 615-ZS-157) was the generous gift of Dr. Gerald Gold (Eli Lilly, Indianapolis, IN). Collagenase (type P) was obtained from Boehringer-Mannheim Biochemicals (Indianapolis, IN).

Statistics. Statistical significance was determined using Student's t-test for unpaired data or analysis of variance. A P value of ≤0.05 was taken as significant. Values presented in the figures and in RESULTS represent means ± SE of at least three observations.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Acute effects of 20 mM glucose and 10 µM carbachol on insulin secretion, IP accumulation, and glucose usage. In the initial series of experiments, the impact of stimulating islets with 20 mM glucose was compared with the impact of stimulating islets with 10 µM carbachol (in the presence of 5 mM glucose). As shown in Fig. 1, 20 mM glucose stimulation resulted in a dramatic augmentation of insulin release from perifused islets. Compared with prestimulatory rates of ~30 pg·islet–1·min–1, insulin secretion increased to >600 pg·islet–1·min–1 during the second phase response. The inclusion of 100 µM diazoxide completely abolished insulin secretion in response to glucose, whereas the muscarinic antagonist atropine (50 µM) had no effect (Fig. 1). In the presence of 5 mM glucose, the addition of 10 µM carbachol to the perifusion medium failed to increase the secretion of insulin.



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 1. Insulin secretion from freshly studied islets: effects of various agonists on secretion rates. Groups of islets were perifused immediately after isolation. For the initial 30 min, they were perifused with 5 mM glucose (G5) to establish basal and stable rates of release. At that time (vertical line), they were then stimulated for 40 min with 20 mM glucose ({circ}), 20 mM glucose + 100 µM diazoxide ({bullet}), 20 mM glucose + 50 µM atropine ({blacktriangleup}), or 5 mM glucose + 10 µM carbachol ({triangleup}). A minimum of 3 experiments were performed under each condition, and values are shown as means ± SE. This and subsequent figures have not been corrected for the dead space in the perifusion apparatus, 2.5 ml or 2.5 min with a flow rate of 1 ml/min.

 
In additional studies, the acute impact of glucose or carbachol on PLC activation was determined in [3H]inositol-prelabeled islets. Levels of labeled IP averaged ~5,100 cpm/40 islets after 30 min of incubation (Table 1, line 1). Both 10 µM carbachol and 20 mM glucose resulted in significant increments in IP accumulation (Table 1, lines 2 and 3). Similarly to its inhibitory effect on glucose-induced insulin secretion, the addition of diazoxide abolished the stimulatory effect of 20 mM glucose on IP accumulation (Table 1, line 4).


View this table:
[in this window]
[in a new window]
  		Table 1. Inositol phosphate accumulation

 
In additional studies, the usage of glucose in the presence of diazoxide or carbachol was determined. After isolation, groups of islets were incubated for 1 h with [5-3H]glucose in the presence of different glucose levels. In the presence of 5 mM glucose alone, usage rates averaged 65.7 ± 2 pmol·islet–1·h–1 (n = 4). Carbachol (10 µM), despite increasing IP accumulation, had no effect on glucose usage rates that now averaged 65.2 ± 4 pmol·islet–1·h–1 (n = 5). In the presence of 20 mM glucose alone, usage rates averaged 220 ± 12 pmol·islet–1·h–1 (n = 6). Despite its marked inhibitory effect on secretion, the addition of 100 µM diazoxide did not adversely impact glucose usage. It now averaged 203 ± 9 pmol·islet–1·h–1 (n = 6).

Chronic effects of 20 mM glucose and 10 µM carbachol on insulin secretion, IP accumulation, and glucose usage. The primary goal of the present studies was to determine the consequences of prolonged exposure to glucose or carbachol on islet physiology. With the control data described above serving as the backdrop, additional studies were conducted. In these experiments, islets were isolated and before the perifusion were incubated for 3 h with 5 mM glucose (control), 5 mM glucose plus 10 µM carbachol, or 20 mM glucose. To disrupt the activation of PLC during this time, atropine or diazoxide was included in some studies.

Control islets incubated for 3 h with 5 mM glucose and subsequently perifused with 20 mM glucose responded, as anticipated, with brisk increment in insulin secretion (Fig. 2). Peak second-phase release rates averaged 375–400 pg·islet–1·h–1 (n = 20). When 20 mM glucose was included during the 3 h incubation, the subsequent secretory response to 20 mM glucose was dramatically deranged. For example, although control islets released insulin at peak rates approaching 400 pg·islet–1·h–1, this value now averaged only 80–90 pg·islet–1·h–1 (n = 10). A similar lesion in the secretory response to 20 mM glucose was also induced by chronic 3 h exposure to 10 µM carbachol as well. Peak release rates now averaged 120–130 pg·islet–1·h–1 (n = 14; Fig. 2).



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 2. Insulin secretion from islets incubated for 3 h with 20 mM glucose or carbachol. Groups of islets were isolated and incubated for 3 h with 5 mM glucose alone (G5, {circ}, control), 20 mM glucose (G20, {blacktriangleup}), or 5 mM glucose + 10 µM carbachol (G5 + C, {triangleup}), as indicated in MATERIALS AND METHODS and RESULTS. After that, islets were perifused for 30 min with 5 mM glucose before stimulation with 20 mM glucose for 40 min (onset of stimulation indicated by vertical line). Values are given as means ± SE. *Significant (P < 0.05) difference between experimental groups and control release values at this time.

 
Attempts were made to block the desensitizing impact of prior 20 mM glucose or carbachol exposure on the insulin secretory process. Diazoxide (100 µM) inclusion, together with 20 mM glucose for the 3-h period before the perifusion, completely abolished the adverse effect of chronic hyperglycemia on islet responsiveness (Fig. 3). In sharp contrast, 50 µM atropine exerted no protective effect against chronic hyperglycemia.



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 3. Effect of diazoxide on 20 mM glucose-induced desensitization of insulin secretion. Two groups of islets were studied. One group ({blacktriangleup}, n = 10; same data as in Fig. 2) was incubated for 3 h with 20 mM glucose before perifusion; the other group ({triangleup}, n = 6) was incubated for 3 h with 20 mM glucose + 100 µM diazoxide before stimulation with 20 mM glucose during subsequent perifusion. *Significant (P < 0.05) difference between experimental groups at these time points.

 
When carbachol was employed to desensitize islets, atropine (50 µM, n = 7), but not diazoxide (100 µM, n = 10; results not shown), significantly altered the adverse impact of sustained cholinergic stimulation on subsequent islet responses to 20 mM glucose (Fig. 4). Most dramatic was atropine's protective effect on sustained second-phase secretion rates. Peak second phase release rates to 20 mM glucose measured during the subsequent perifusion now averaged >400 pg·islet–1·h–1, a response similar to that evoked from control islets incubated for 3 h with 5 mM glucose alone.



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4. Effects of atropine on carbachol-induced desensitization of insulin secretion. Three groups of islets were studied. The 1st group (control, {circ} data; also given in Fig. 2 and indicated by G5), after 3-h incubation with 5 mM glucose alone, was stimulated with 20 mM glucose during dynamic perifusion; the 2nd group ({triangleup} data, also given in Fig. 2 and indicated by G5 + C) was incubated for 3 h with 5 mM glucose + 10 µM carbachol before stimulation with 20 mM glucose; the 3rd group ({circ} indicated by G5 + C + A) was incubated for 3 h with 5 mM glucose + 10 µM carbachol + 50 µM atropine before being stimulated with 20 mM glucose. *Significant difference from G5; #significant difference from G5 + C.

 
Additional studies were then conducted to explore the effects of chronic hyperglycemia and cholinergic stimulation on IP accumulation in islets. In these studies, control islets were incubated for 3 h with 5 mM glucose plus [3H]inositol. In addition to the label, various compounds listed in Table 1 were also included during the incubation. After a washing, IP levels in response to various stimulants were determined. Compared with islets labeled in the presence of 5 mM glucose, inclusion of 10 µM carbachol or 20 mM glucose during this period significantly reduced IP responses to a subsequent 20 mM glucose stimulus (Table 1, line 3 vs. lines 6 and 10). Atropine protected islet IP responses against the adverse impact of carbachol but had no such beneficial action against 20 mM glucose (Table 7, lines 6, 7, and 11). Diazoxide had no effect on carbachol-induced desensitization of IP responses (Table 1, line 6 vs. line 8).

In our studies exploring the potential protective effect of diazoxide on 20 mM glucose-induced desensitization of IP accumulation, little protective effect was noted (Table 1, line 12). We reasoned that the cellular accumulation of diazoxide during the 3-h incubation and our failure to completely remove it during the brief washing period was in all likelihood responsible for this observation. Thus its persistence during the subsequent 30-min stimulation period with 20 mM glucose may have masked any potential protective effect of diazoxide against 20 mM glucose-induced desensitization of PLC. To address this issue, islets were labeled with [3H]inositol in the presence of 20 mM glucose ± 100 µM diazoxide. After this 3-h period, islets were perifused for 30 min with 5 mM glucose alone and then stimulated for 40 min with 20 mM glucose. We previously observed that this type of protocol allowed us to establish that diazoxide completely protected the secretory process from the adverse impact of chronic, 20-mM glucose exposure (see Fig. 3). The efflux results are presented in Fig. 5. By use of this approach to measure PLC activation, 100 µM diazoxide provided complete protection against the adverse effects of 20 mM glucose on the subsequent PLC response.



View larger version (30K):
[in this window]
[in a new window]
  		Fig. 5. Fractional [3H]inositol efflux rates from perifused islets. Three groups of islets were studied. All groups were incubated for 3 h in [3H]inositol-containing medium to label their phosphoinositide pools. The 1st group (controls, {circ}) contained 5 mM glucose during this time; the 2nd group ({blacktriangleup}) contained 20 mM glucose; the 3rd group ({triangleup}) contained 20 mM glucose + 100 µM diazoxide. After labeling period, all groups were perifused with 5 mM glucose for 30 min and then stimulated with 20 mM glucose. Fractional efflux rates of [3H]inositol are depicted.

 
In studies where the effects of prior carbachol or 20 mM glucose exposure on glucose utilization were determined, we found that despite profound reductions in PLC activation, neither compound had any adverse effect on glucose usage rates. Islets exposed to 5 mM glucose for 3 h and then 20 mM glucose for 1 h utilized glucose at the rate of 175 ± 26 (n = 5) pmol·islet–1·h–1. Prior exposure to 10 µM carbachol or 20 mM glucose for 3 h resulted in 20 mM glucose usage rates of 171 ± 22 (n = 3) or 182 ± 15 (n = 6) pmol·islet–1·h–1, respectively.

Effects of chronic 20 mM glucose and carbachol exposure on insulin secretion: effects of forskolin. As shown in Table 2, compared with islets exposed to 5 mM glucose, prior 3-h exposure to 20 mM glucose, but not carbachol, significantly reduced insulin stores when measured after the perifusion (Table 1, line 1 vs. lines 3 and 4). Similarly to its protective effect on both secretion and PLC activation, diazoxide, but not atropine, prevented this effect (line 2). It might be reasonably argued that the underlying secretory lesion induced by chronic hyperglycemia is simply a result of lowered insulin stores in the islet. To test this hypothesis, islets were exposed to 20 mM glucose or 10 µM carbachol for 3 h and then stimulated during the dynamic perifusion with the combination of 20 mM glucose plus 500 nM forskolin, an adenylate cyclase activator (32). Forskolin exerted a significant restorative effect on these islets, an effect that was significant, regardless of the protocol used to desensitize them (Fig. 6). For example, islets desensitized by prior exposure to 20 mM glucose or 10 µM carbachol for 3 h released insulin at rates of ~100 pg·islet–1·h–1 during peak second phase secretion (Fig. 6). After 3 h of exposure to 20 mM glucose, the addition of 500 nM forskolin during the subsequent perifusion with 20 mM glucose increased the release rate to 300–400 pg·islet–1·min–1 (n = 6; Fig. 6A). Even more dramatic was the impact of forskolin on carbachol-desensitized islets that were stimulated with 20 mM glucose (Fig. 6B). Peak second-phase release rates of 700–800 pg·islet–1·min–1 (n = 7) were noted.


View this table:
[in this window]
[in a new window]
  		Table 2. Insulin content in isolated islets

 


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 6. Effects of forskolin on insulin secretion rates from glucose- or carbachol-desensitized islets. A: after 3 h in 20 mM glucose, islets were perifused for 30 min with 5 mM glucose and for an additional 40 min with 20 mM glucose alone ({blacktriangleup}) or 20 mM glucose + 500 nM forskolin ({bullet}). B: after 3 h in 5 mM glucose + 10 µM carbachol, islets were perifused for 30 min with 5 mM glucose and for an additional 40 min with 20 mM glucose alone ({triangleup}) or 20 mM glucose + 500 nM forskolin ({bullet}). *Significant (P < 0.05) difference between groups at this time.

 
It should be emphasized, however, that, although 500 nM forskolin exerted a strong stimulatory effect on 20 mM glucose-desensitized islets, it did not normalize secretion from them. For example, control islets maintained for 3 h with 5 mM glucose and subsequently stimulated with the combination of 20 mM glucose plus 500 nM forskolin displayed greater secretory responses than those evoked from desensitized islets. During the final 20 min of stimulation, release rates to the combination of glucose plus forskolin averaged 1,002 ± 75 pg·islet–1·min–1 (n = 4; results not shown) from these islets.

Time dependence of 20 mM glucose-induced desensitization of PLC activation and insulin secretion. In the final series of experiments, we explored the impact of reducing the exposure period to 20 mM glucose from 3 h to 1.5 h. The results are given in Fig. 7. A prior 90-min exposure period to 20 mM glucose resulted in significant reductions in the ability of a subsequent 20 mM glucose stimulus to activate PLC, monitored by fractional efflux rates, and stimulate insulin secretion.



View larger version (23K):
[in this window]
[in a new window]
  		Fig. 7. Insulin secretion and fractional [3H]inositol efflux rates from perifused islets. Two groups of islets were studied. Both groups were incubated for 1.5 h in a [3H]inositol-containing medium to label their phosphoinositide pools. One group ({bullet}) contained 5 mM glucose during this time (controls), the other group ({circ}) contained 20 mM glucose during the labeling period. After labeling period, both groups were perifused with 5 mM glucose for 30 min and then stimulated with 20 mM glucose. Values are given as means ± SE. *Significant (P < 0.05) difference between groups at this time.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The {beta}-cell odyssey from being exquisitely glucose sensitive to glucose insensitive is a complex journey, the steps of which are only slowly being identified. Their elucidation, however, is of paramount importance to our understanding of how and why the {beta}-cell fails or decompensates in type 2 diabetes. Considering their potential pathophysiological and therapeutic potential, we focused on identifying the earliest biochemical anomalies in desensitized islets. The approach utilized in the present studies was to use a highly responsive and sensitive (to glucose stimulation) system, the collagenase-isolated rat islet, and subject it to a number of manipulations. Because glucose exerts multiple effects on the {beta}-cell, from increases in glucose metabolites to second messengers to gene transcription, we wanted to compare the effects of glucose with those induced by a compound, carbachol, whose only established effect is the activation of {beta}-cell PLC (14, 18, 55). This cholinergically activated process requires the M3 muscarinic receptor type and generates a number of important second messengers, including IPs and diacylglycerol (7, 28, 30). One central question was to determine the role of PLC activation in determining islet sensitivity to glucose and its vulnerability to sustained hyperglycemia.

In the initial series of experiments, the acute effects of 20 mM glucose or carbachol on several parameters of {beta}-cell activation were assessed. Not surprisingly, 20 mM glucose stimulation resulted in a dramatic augmentation of insulin secretion, a response that paralleled in magnitude findings made using the perfused pancreas or human islets studied in vivo using the hyperglycemic clamp technique (15–17, 20, 26, 34). The secretory response to glucose was abolished by diazoxide but was unaffected by the cholinergic antagonist atropine. In sharp contrast to 20 mM glucose, carbachol (in the presence of 5 mM glucose) did not alter insulin secretion rates. The exquisite glucose dependence of cholinergic stimulation of insulin secretion is well established (18, 23).

By use of labeled IP accumulation to monitor its activity, 20 mM glucose significantly increased PLC activation in parallel with secretion. The stimulatory effect of glucose was abolished by diazoxide but was left intact by atropine. In contrast to its ineffectiveness on the secretory process, carbachol also significantly increased PLC activation.

An analysis of glucose usage rates under these different experimental conditions revealed the following. First, rates of glucose metabolism in the presence of 5 mM glucose averaged 60–70 pmol·islet–1·h–1. Carbachol did not affect this process. Second, raising the glucose level to 20 mM increased usage about threefold. Third, diazoxide, despite its profound inhibitory effect on 20 mM glucose-induced insulin secretion and PLC activation, exerted no inhibitory effect on glucose usage rates by the islet. The failure of diazoxide to alter glucose metabolism has been noted previously (3, 5).

After first establishing some of the characteristics of acute {beta}-cell activation by 20 mM glucose or carbachol, we focused our attention on how chronic exposure to these compounds affects this cell. In both instances, chronic, sustained 3-h exposure to high glucose or carbachol profoundly altered the insulin-secretory process. Peak second-phase secretion rates in response to 20 mM glucose measured during a subsequent dynamic perifusion, after basal release was taken into account, were reduced by >75%. The inhibitory effect of prior 20 mM glucose was paralleled by a significant reduction in PLC activation but no untoward effect on metabolism. Of particular interest in terms of understanding the biochemical lesion involved and its potential as a target for therapeutic intervention, diazoxide protected both PLC and the secretory process from 20 mM glucose-induced desensitization. This protective action occurred despite the inability of diazoxide to alter glucose metabolism. This suggests that, at least with this model of {beta}-cell inactivation, altered PLC activation may be critically involved and is the potential Achilles' heel of the secretory process.

It should also be noted that it proved possible to induce significant defects in secretion and PLC activation after only 1.5 h of exposure to 20 mM glucose. A fertile future area of investigation, perhaps, is an analysis of the impact of moderate (6–10 mM) hyperglycemia on these two parameters of {beta}-cell activation.

Our findings made with carbachol further support the importance of PLC activation as an integral component in the induction of desensitization. Unlike glucose, a nutrient that exerts multiple effects on the {beta}-cell, cholinergic stimulants exert one critically important physiological effect, the activation of PLC (18). They do not stimulate insulin secretion or lower insulin stores of the islet after chronic exposure to them. Thus their negative effect, as reported here, cannot be due to excessive stimulation of the insulin-secretory machinery or to lowered insulin content of the {beta}-cell. They have no effect on glucose usage rates, thus excluding excessive accumulation of metabolic products, toxic oxygen radicals, or oxidative stress as underlying its adverse effect on the secretory process. Most importantly, as demonstrated herein, carbachol's negative effects on the subsequent activation of both PLC and secretion are effectively thwarted by atropine. Interestingly, atropine did not protect the {beta}-cell from 20 mM glucose, attesting to its specificity and supporting further the role of PLC.

We considered the possibility that, at least in the case of glucose, the diminished availability of releasable insulin might contribute to alterations in hormone secretion. Indeed, compared with carbachol-pretreated islets, chronic exposure to 20 mM glucose lowered insulin content, at least when measured after the perifusion. However, as demonstrated when forskolin was included during the perifusion with 20 mM glucose, despite the decline in total insulin stores, these islets are still quite responsive, and release rates comparable with those achieved from control 5 mM glucose-pretreated islets were observed. However, compared with the response of carbachol-pretreated islets, there was an observable difference suggesting that insulin stores might contribute in some small way to the secretory lesion. The restorative effect of forskolin on the secretory process is reminiscent of the effect of the gut hormone glucagon-like peptide-1 on secretion from desensitized islets (51).

When taken in its entirety, the following sequence of events seems reasonable in light of what has been previously reported (4, 9–11, 33, 52, 54), combined with the present findings. Acutely, both glucose and carbachol activate islet PLC. This event alone, however, is ineffective in activating secretion to any appreciable extent. Additional fail-safe substrates provided for by glucose supplement the generation of PLC-derived second messengers, culminating in a brisk biphasic insulin secretory response. The signals include not only metabolites and cofactors but also other second messengers such as cAMP (13, 24, 25, 45). However, the events associated with prolonged stimulation by glucose, despite initially activating the secretory process, plant the seeds for eventual {beta}-cell failure or desensitization. Because chronic carbachol exposure faithfully reproduces the negative impact of chronic 20 mM glucose on the secretory process, and does so without increasing glucose metabolism or insulin secretion, a reasonable working hypothesis is that excessive stimulation of PLC underlies aberrant secretion that is irrelevant to the agonist used to activate the enzyme. The primary common denominator between carbachol- and glucose-induced desensitization is PLC.

The regulation of PLC has been studied in detail by Rhee and colleagues (29, 30) and Ryu et al. (31), and their findings may be particularly relevant to the {beta}-cell and the biochemical events described herein. In their comprehensive studies, they found that PLC was susceptible to negative feedback regulation by either PKC or PKA. Thus compounds that activate PKC or elevate cAMP have the potential to impair activation of PLC. We previously observed (44) that, similarly to the effects reported here and elsewhere with sustained glucose and carbachol exposure (51), prolonged exposure to forskolin or IBMX also impairs glucose-induced PLC activation and results in defective insulin secretion as well. This suggests that, regardless of the compounds used to induce desensitization, their ability to impair secretion might be dependent upon their ability to inactivate PLC. Our working hypothesis, and one supported by a number of observations (28, 40, 46, 47), is that although short-term exposure to compounds that activate PLC positively affect secretion, playing an important role in both biphasic secretion and the induction of time-dependent sensitization or memory, prolonged activation of the enzyme sets into motion a series of events that inhibit its activation.

Most recently, it has been suggested that an imposed period of {beta}-cell rest might help to restore the secretory responsiveness of the cell. It has been reported that diazoxide, which inhibits secretion, protects against chronic hyperglycemia (2, 35). These studies both confirm and expand the concept put forth almost 30 yr ago that diazoxide might be useful in the therapy of diabetes (19). The protective action of diazoxide against sustained hyperglycemia is thought to be due to a direct {beta}-cell effect (27) and has been confirmed in vitro as well (8). In the present report, we confirmed the protective action of the KATP channel opener against hyperglycemia-induced impaired secretion. This protective effect was not due to the ability of diazoxide to reduce the usage of glucose. Diazoxide did not affect glucose metabolism, as shown here and elsewhere (3, 5); its protection appeared to be due, at least in part, to its ability to interfere with glucose-induced PLC activation. In a similar fashion, the muscarinic antagonist atropine also blocked carbachol-induced desensitization, presumably by interfering with PLC activation. Finally, the observations made with this endocrine system reinforce what has been noted with other systems as well; the sustained stimulation of those pathways that so elegantly control hormone secretion can, if their stimulation is unrestrained, impair target cell performance. In the {beta}-cell, this adverse process culminates in diabetes, and efforts should now be made to utilize this information therapeutically.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
These studies were supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-41230 and DK-45735.


   FOOTNOTES
 

Address for reprint requests and other correspondence: W. S. Zawalich, Yale University School of Nursing, 100 Church Street St. PO Box 9740, New Haven, CT 06536-0740 (e-mail: walter.zawalich{at}yale.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Albano JD, Ekins RP, Maritz G, and Turner RC. A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol 70: 487–509, 1972.
  2. Alemzadeh R and Tushaus KK. Modulation of the adipoinsular axis in prediabetic Zucker diabetic fatty rats by diazoxide. Endocrinology 145: 5476–5484, 2004.[Abstract/Free Full Text]
  3. Ashcroft SJ, Hedeskov CJ, and Randle PJ. Glucose metabolism in mouse pancreatic islets. Biochem J 118: 143–154, 1970.[ISI][Medline]
  4. Axen KV, Schubart UK, Blake AD, and Fleischer N. Role of Ca2+ in secretagogue-stimulated breakdown of phosphatidylinositol in rat pancreatic islets. J Clin Invest 72: 13–21, 1983.[ISI][Medline]
  5. Bergsten P, Gylfe E, Wesslen N, and Hellman B. Diazoxide unmasks glucose inhibition of insulin release by counteracting entry of Ca2+. Am J Physiol Endocrinol Metab 255: E422–E427, 1988.[Abstract/Free Full Text]
  6. Berridge MJ, Dawson RM, Downes CP, Heslop JP, and Irvine RP. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J 212: 473–482, 1983.[ISI][Medline]
  7. Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem 56: 159–193, 1987.[ISI][Medline]
  8. Björklund A and Grill V. B-cell insensitivity in vitro: reversal by diazoxide entails more than one event in stimulus-secretion coupling. Endocrinology 132: 1319–1328, 1993.[Abstract]
  9. Bolaffi JL, Heldt A, Lewis LD, and Grodsky GM. The third phase of in vitro insulin secretion. Evidence for glucose insensitivity. Diabetes 35: 370–373, 1986.[Abstract]
  10. Bolaffi JL, Bruno Z, Heldt A, and Grodsky GM. Characteristics of desensitization of insulin secretion in fully in vitro systems. Endocrinology 122: 1801–1809, 1988.[Abstract]
  11. Bolaffi JL, Rodd GG, Ma YH, Bright D, and Grodsky GM. The role of Ca2+-related events in glucose-stimulated desensitization of insulin secretion. Endocrinology 129: 2131–2138, 1991.[Abstract]
  12. Borle AB, Uchikawa T, and Anderson JH. Computer simulation and interpretation of 45Ca efflux profile patterns. J Memr Biol 68: 37–46, 1982.[CrossRef][ISI][Medline]
  13. Charles MA, Fanska R, Schmid FG, Forsham P, and Grodsky GM. Adenosine 3' 5'-monophosphate in pancreatic islets: glucose-induced insulin release. Science 179: 569–571, 1973.[Abstract/Free Full Text]
  14. Duttaroy A, Zimlike CL, Gautam D, Cui Y, Mears D, and Wess J. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in M3 muscarinic acetylcholine receptor-deficient mice. Diabetes 53: 1714–1720, 2004.[Abstract/Free Full Text]
  15. Elahi D, Muller DC, McAloon-Dyke M, Tobin JD, and Andres R. The effect of age on insulin response and glucose utilization during four hyperglycemic plateaus. Exp Gerontol 28: 393–409, 1993.[CrossRef][ISI][Medline]
  16. Elahi D. In praise of the hyperglycemic clamp: a method for assessment of {beta}-cell sensitivity and insulin resistance. Diabetes Care 19: 278–286, 1996.[Abstract]
  17. Gerich JE, Charles MA, and Grodsky GM. Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. J Clin Invest 54: 833–841, 1974.[ISI][Medline]
  18. Gilon P and Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic {beta}-cell function. Endocr Rev 22: 565–604, 2001.[Abstract/Free Full Text]
  19. Greenwood RH, Mahler RF, and Hales CN. Improvement in insulin secretion in diabetes after diazoxide. Lancet 7957: 444–447, 1976.
  20. Grill V, Adamson U, and Cerasi E. Immediate and time-dependent effects of glucose on insulin release from rat pancreatic tissue. J Clin Invest 61: 1034–1043, 1978.[ISI][Medline]
  21. Grodsky GM. A new phase of insulin secretion. How will it contribute to our understanding of {beta}-cell function? Diabetes 38: 673–678, 1989.[Abstract]
  22. Grodsky GM and Bolaffi JL. Desensitization of the insulin-secreting beta cell. J Cell Biol 48: 3–11, 1992.
  23. Loubatieres-Mariani MM, Chapal J, Alric R, and Loubatieres A. Studies of the cholinergic receptor involved in the secretion of insulin using isolated perfused rat pancreas. Diabetologia 9: 439–476, 1973.[CrossRef][ISI][Medline]
  24. Malaisse WJ, Hutton JC, Kawazu S, and Sener A. The stimulus-secretion coupling of glucose-induced insulin release. Metabolic effects of menadione in isolated islets. Eur J Biochem 87: 121–130, 1978.[CrossRef][ISI][Medline]
  25. Malaisse WJ, Sener A, Herchuelz A, and Hutton JC. Insulin release: the fuel hypothesis. Metabolism 28: 373–386, 1979.[CrossRef][ISI][Medline]
  26. O'Conner MD, Landahl H, and Grodsky GM. Comparison of storage- and signal-limited models of pancreatic insulin secretion. Am J Physiol Regul Integr Comp Physiol 238: R378–R389, 1980.[Abstract/Free Full Text]
  27. Raju B and Cryer PE. Mechanism, temporal patterns, and magnitude of the metabolic responses to the KATP channel agonist diazoxide. Am J Physiol Endocrinol Metab 288: E80–E85, 2005.[Abstract/Free Full Text]
  28. Rasmussen H, Zawalich KC, Ganesan S, Calle R, and Zawalich WS. Physiology and pathophysiology of insulin secretion (Review). Diabetes Care 13: 655–666, 1990.[Abstract]
  29. Rhee SG and Choi KD. Regulation of inositol phospholipid-specific phospholipase C isozymes. J Biol Chem 267: 12393–12396, 1992.[Free Full Text]
  30. Rhee SG and Bae YS. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem 272: 15045–15048, 1997.[Free Full Text]
  31. Ryu SH, Kim UH, Wahl WI, Brown AB, Carpenter G, Huang KP, and Rhee SG. Feedback regulation of phospholipase C-{beta} by protein kinase C. J Biol Chem 265: 17941–17945, 1990.[Abstract/Free Full Text]
  32. Seamon KB, Padgett W, and Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 78: 3363–3367, 1981.[Abstract/Free Full Text]
  33. Vadakekalam J, Rabaglia ME, Chen QH, and Metz SA. Role for GTP in glucose-induced phospholipase C activation in pancreatic islets. Am J Physiol Endocrinol Metab 271: E85–E95, 1996.[Abstract/Free Full Text]
  34. Van Haeften TW, Boonstra E, Veneman TF, Gerich JE, and van der Veen EA. Dose-response characteristics for glucose-stimulated insulin release in man and assessment of influence of glucose on arginine-stimulated insulin release. Metabolism 39: 1292–1299, 1990.[CrossRef][ISI][Medline]
  35. Yoshikawa H, Ma Z, Björklund A, and Grill V. Short-term intermittent exposure to diazoxide improves functional performance of {beta}-cells in a high-glucose environment. Am J Physiol Endocrinol Metab 287: E1202–E1208, 2004.[Abstract/Free Full Text]
  36. Zawalich WS, Rognstad R, Pagliara AS, and Matschinsky FM. A comparison of the utilization rates and hormone-releasing actions of glucose, mannose, and fructose in isolated pancreatic islets. J Biol Chem 252: 8519–8523, 1977.[Free Full Text]
  37. Zawalich WS, Diaz VA, and Zawalich KC. Cholecystokinin-induced alterations in beta-cell sensitivity. Duration, specificity, and involvement of phosphoinositide metabolism. Diabetes 36: 1420–1424, 1987.[Abstract]
  38. Zawalich WS, Takuwa N, Takuwa Y, Diaz VA, and Rasmussen H. Interactions of cholecystokinin and glucose in rat pancreatic islets. Diabetes 36: 426–433, 1987.[Abstract]
  39. Zawalich WS, Diaz VA, and Zawalich KC. Influence of cAMP and calcium on [3H]inositol efflux, inositol phosphate accumulation, and insulin release from isolated rat islets (published erratum appears in Diabetes 38: 3, 1989). Diabetes 37: 1478–1483, 1988.[Abstract]
  40. Zawalich WS, Diaz VA, and Zawalich KC. Role of phosphoinositide metabolism in induction of memory in isolated perifused rat islets. Am J Physiol Endocrinol Metab 254: E609–E616, 1988.[Abstract/Free Full Text]
  41. Zawalich WS. Phosphoinositide hydrolysis and insulin secretion in response to glucose stimulation are impaired in isolated rat islets by prolonged exposure to the sulfonylurea tolbutamide. Endocrinology 125: 281–286, 1989.[Abstract]
  42. Zawalich WS, Zawalich KC, and Rasmussen H. The conditions under which rat islets are labeled with [3H]inositol alter the subsequent responses of these islets to a high glucose concentration. Biochem J 259: 743–749, 1989.[ISI][Medline]
  43. Zawalich WS. Multiple effects of increases in phosphoinositide hydrolysis on islets and their relationship to changing patterns of insulin secretion. Diabetes Res 13: 101–111, 1990.[ISI][Medline]
  44. Zawalich WS and Zawalich KC. Forskolin-induced desensitization of pancreatic {beta}-cell insulin secretory responsiveness: possible involvement of impaired information flow in the inositol-lipid cycle. Endocrinology 126: 2307–2312, 1990.[Abstract]
  45. Zawalich WS, Zawalich KC, and Rasmussen H. Control of insulin secretion: a model involving Ca2+, cAMP and diacylglycerol. Mol Cell Endocrinol 70: 119–137, 1990.[CrossRef][ISI][Medline]
  46. Zawalich WS and Zawalich KC. Glucosamine-induced desensitization of beta-cell responses: possible involvement of impaired information flow in the phosphoinositide cycle. Endocrinology 130: 3135–3142, 1992.[Abstract]
  47. Zawalich WS and Kelley GG. The pathogenesis of NIDDM: the role of the pancreatic beta cell. Diabetologia 38: 986–991, 1995.[ISI][Medline]
  48. Zawalich WS, Zawalich KC, and Kelley GG. Effects of short term culturing on islet phosphoinositide and insulin secretory responses to glucose and carbachol. Acta Diabetol 32: 158–164, 1995.[CrossRef][ISI][Medline]
  49. Zawalich WS. Regulation of insulin secretion by phosphoinositide-specific phospholipase C and protein kinase C activation. Diabetes Rev 4: 160–176, 1996.
  50. Zawalich WS and Zawalich KC. Species differences in the induction of time-dependent potentiation of insulin secretion. Endocrinology 137: 1664–1669, 1996.[Abstract]
  51. Zawalich WS and Zawalich KC. Glucagon-like peptide-1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol. Metabolism 45: 273–278, 1996.[CrossRef][ISI][Medline]
  52. Zawalich WS and Zawalich KC. Regulation of insulin secretion by phospholipase C. Am J Physiol Endocrinol Metab 271: E409–E416, 1996.[Abstract/Free Full Text]
  53. Zawalich WS, Zawalich KC, and Kelley GG. Time-dependent effects of cholinergic stimulation on beta cell responsiveness. Eur J Physiol 432: 589–596, 1996.[CrossRef][ISI][Medline]
  54. Zawalich WS, Bonnet-Eymard M, and Zawalich KC. Glucose-induced desensitization of the pancreatic {beta}-cell is species dependent. Am J Physiol Endocrinol Metab 275: E917–E924, 1998.[Abstract/Free Full Text]
  55. Zawalich WS, Zawalich KC, Tesz GJ, Taketo MM, Sterpka J, Philbrick W, and Matsui M. Effects of muscarinic receptor type 3 knockout on mouse islets secretory responses. Biochem Biophys Res Commun 315: 872–876, 2004.[CrossRef][ISI][Medline]



This article has been cited by other articles:


Home page
 DiabetesHome page
I. R. Sweet and M. Gilbert
Contribution of Calcium Influx in Mediating Glucose-Stimulated Oxygen Consumption in Pancreatic Islets
Diabetes, December 1, 2006; 55(12): 3509 - 3519.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. Yamazaki, K. C. Zawalich, and W. S. Zawalich
Desensitization of the pancreatic beta-cell: effects of sustained physiological hyperglycemia and potassium
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): H1381 - H1387.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/1/E26    most recent
00149.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamazaki, H.
Right arrow Articles by Zawalich, W. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamazaki, H.
Right arrow Articles by Zawalich, W. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.